Drug intelligence / Profile preview

B836-ADC

Development stage: Preclinical
Lead developer: Nanolattix
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

B836-ADC is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by Shanxi Naan Biotechnology. It is designed for the treatment of solid tumors, specifically breast cancer, colorectal cancer, and gastric cancer. As a bispecific ADC, it utilizes a dual-targeting antibody scaffold to enhance tumor selectivity and facilitate the delivery of a cytotoxic payload directly to malignant cells. The program is currently in the preclinical stage of development and is intended for intravenous administration.

Targets

F3 (Tissue factor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on B836-ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B836-ADC.

Explore the full profile